Elutia Inc. sells its EluPro™ and CanGaroo® bioenvelopes to Boston Scientific Corporation for $88 million.
Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform.
The sale fully funds advancement of NXT-41 in breast reconstruction.
Proprietary Technology Validation
Sale demonstrates the success of Elutia's drug-eluting biologic technology platform.
Financial Transformation
The sale provides non-dilutive funding for NXT-41 advancement and commercialization.
Strategic Focus
Enables Elutia to dedicate resources to SimpliDerm franchise and drug-eluting pipeline in the breast reconstruction market.
Shareholder Value
Transaction signifies a pivotal advance, strengthening Elutia's financial position.
- Balance Sheet Transformation to eliminate debt and reduce burn rate.
- Non-dilutive funding for future operations and commercialization.
- Focus on advancing SimpliDerm franchise and drug-eluting pipeline in the breast reconstruction market.
The sale of the BioEnvelope business marks a significant milestone for Elutia, positioning the company for focused growth and development. The transaction not only strengthens the financial position but also underscores the value of Elutia's proprietary technology platform.